Founded in 2019 by Jordi Carrera and Rafel Bru former founders of STAT-Dx, a company sold to QIAGEN in 2018 for 191 million dollars. Round led by Alta Life Sciences and Kurma Partners (France) and supported by Axis Participaciones Empresariales (ICO) and Sofimac Innovation (France). Financing to validate the technology and build the first units. Barcelona, 7 July 2020.- DeepUll announced today the closing of a 3.5 million…
Breakthrough approach to developing first-in-class treatments for metastatic cancer patients Financing to progress lead candidate to proof of clinical efficacy Supported by strong European investor syndicate including Alta Life Sciences, Asabys Partners, Bpifrance – InnoBio 2, Fund+ and Ysios Capital Barcelona, Spain, June 16th 2020: Ona Therapeutics, which is focused on the discovery and development of therapeutic biologics to treat metastatic cancer, announces today the closing of a €30 million…
Barcelona, 17 de junio de 2020 INBRAIN desarrolla dispositivos de grafeno inteligentes para la modulación electrónica neuronal contra trastornos cerebrales como el Parkinson y la Epilepsia entre otros Asabys Y Alta han liderado la inversión en INBRAIN para desarrollar una tecnología basada en Grafeno para la modulación electrónica neuronal que permite, tras la implantación intracerebral de un innovador electrodo, decodificar señales neuronales con alta fidelidad y producir una respuesta terapéutica…
Newly appointed VP of Business Development and SVP of Clinical Development each bring to Sanifit over 20 years of industry experience Palma, Spain and San Diego, USA, 01 June 2020 – Sanifit, a clinical-stage biopharmaceutical company focused on developing treatments for calcification disorders, is delighted to announce two new appointments to its Executive leadership team, with immediate effect. Hans Christian Keller joins the Company as Vice President of Business Development, and…
Alta Life Sciences and the Centre for Technological and Industrial Development (CDTI) invest in new company that will develop portfolio of new medicines to address CNS diseases Barcelona, Spain, May 26, 2020 – Accure Therapeutics, a new pharma R&D player in the Central Nervous System (CNS) field, announces today its launch with a Series A round of funding totalling €7.6 million ($8.1M). The funding round was led by Alta Life…
Top line data to be presented at 2019 Scientific Sessions of American Heart Association Webcast to be held on Monday 18 November at 11.00 ET Palma, Spain and San Diego, USA, 30 October 2019 – Sanifit, a clinical-stage biopharmaceutical company focused on treatments for progressive vascular calcification disorders, today announced that the international Phase 2b CaLIPSO study of SNF472 in patients with end stage kidney disease (ESKD) on hemodialysis has…
Sanifit, a clinical-stage biopharmaceutical company focused on treatments for progressive vascular calcification disorders that is part of Alta Life Sciences portfolio, has been named by FierceBiotech as one of 2019’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry. In June 2019 Sanifit announced the completion of a €72.2 million (USD 80.9 million) private fundraising to further accelerate the clinical development…
Proceeds to enable progression of orphan designated lead candidate SNF472 into pivotal phase 3 trial for treatment of calciphylaxis Round led by Spanish investor Caixa Capital Risc Columbus Venture Partners joins Alta Life Sciences as new investors, in addition to international consortium of existing shareholders Palma, Spain and San Diego, USA, 26 June 2019 – Sanifit, a clinical-stage biopharmaceutical company focused on treatments for progressive vascular calcification disorders, today announced the…
The round led by Alta Life Sciences, will reinforce the most advanced and accurate symptom checker, the only clinically validated in the world Start-up investors such as European-focused Castel Capital, French-based Naos, as well as other “business angels”, have also joined the round Barcelona, 12th of September 2018. Mediktor announces the closure of a Series A funding round for an amount of 3 million euros. Alta Life Sciences Spain I…
Alta Life Sciences is leading a Series A round of 4 million euros to finance the clinical development of Bionure’s lead compound BN201, that has demonstrated its potential to promote neuroprotection and remyelination in the preclinical phase, offering a game-changing solution for neurodegenerative diseases. Bionure, Barcelona based biotech company that develops neuroprotectant agents to treat neurodegenerative diseases primarily focusing on rare ophthalmologic diseases as Acute Optic Neuritis (AON) and Neuromyelitis…
